Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
Sarah K MacklinStephanie L HinesPashtoon M KasiPublished in: Hereditary cancer in clinical practice (2020)
Historical survival in patients with advanced and metastatic pancreas cancer is poor. Results of this DDR-subset of patients do show significantly superior outcomes, likely secondary to exposure to platinum drugs. This data, alongside other similar cohorts, would favor the DDR-genes being a predictive marker with improved survival if exposed to these drugs and the new class of drugs, PARP-inhibitors.
Keyphrases
- dna damage
- end stage renal disease
- dna repair
- newly diagnosed
- small cell lung cancer
- chronic kidney disease
- squamous cell carcinoma
- ejection fraction
- oxidative stress
- peritoneal dialysis
- drug induced
- electronic health record
- prognostic factors
- big data
- adipose tissue
- dna methylation
- artificial intelligence
- transcription factor